Literature DB >> 29480816

Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes.

Ikram Ullah1, Govindasamy-Muralidharan Karthik1, Amjad Alkodsi2, Una Kjällquist1, Gustav Stålhammar1, John Lövrot1, Nelson-Fuentes Martinez3, Jens Lagergren4, Sampsa Hautaniemi2, Johan Hartman1,3, Jonas Bergh1,5.   

Abstract

Metastatic breast cancers are still incurable. Characterizing the evolutionary landscape of these cancers, including the role of metastatic axillary lymph nodes (ALNs) in seeding distant organ metastasis, can provide a rational basis for effective treatments. Here, we have described the genomic analyses of the primary tumors and metastatic lesions from 99 samples obtained from 20 patients with breast cancer. Our evolutionary analyses revealed diverse spreading and seeding patterns that govern tumor progression. Although linear evolution to successive metastatic sites was common, parallel evolution from the primary tumor to multiple distant sites was also evident. Metastatic spreading was frequently coupled with polyclonal seeding, in which multiple metastatic subclones originated from the primary tumor and/or other distant metastases. Synchronous ALN metastasis, a well-established prognosticator of breast cancer, was not involved in seeding the distant metastasis, suggesting a hematogenous route for cancer dissemination. Clonal evolution coincided frequently with emerging driver alterations and evolving mutational processes, notably an increase in apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like-associated (APOBEC-associated) mutagenesis. Our data provide genomic evidence for a role of ALN metastasis in seeding distant organ metastasis and elucidate the evolving mutational landscape during cancer progression.

Entities:  

Keywords:  Breast cancer; Genetics; Lymph; Molecular genetics; Oncology

Mesh:

Year:  2018        PMID: 29480816      PMCID: PMC5873882          DOI: 10.1172/JCI96149

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

Review 2.  Karnofsky Memorial Lecture. Natural history of small breast cancers.

Authors:  S Hellman
Journal:  J Clin Oncol       Date:  1994-10       Impact factor: 44.544

3.  Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.

Authors:  Marco Colleoni; David Zahrieh; Richard D Gelber; Stig B Holmberg; Jan E Mattsson; Carl-Magnus Rudenstam; Jurij Lindtner; Darja Erzen; Raymond Snyder; John Collins; Martin F Fey; Beat Thürlimann; Diana Crivellari; Elizabeth Murray; Caesar Mendiola; Olivia Pagani; Monica Castiglione-Gertsch; Alan S Coates; Karen Price; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

4.  Selection and adaptation during metastatic cancer progression.

Authors:  Christoph A Klein
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

5.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

6.  Metastatic patterns of cancers: results from a large autopsy study.

Authors:  Guy Disibio; Samuel W French
Journal:  Arch Pathol Lab Med       Date:  2008-06       Impact factor: 5.534

7.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Authors:  R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard
Journal:  Lancet       Date:  2011-12-05       Impact factor: 79.321

8.  Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

Authors:  Lucy R Yates; Moritz Gerstung; Stian Knappskog; Christine Desmedt; Gunes Gundem; Peter Van Loo; Turid Aas; Ludmil B Alexandrov; Denis Larsimont; Helen Davies; Yilong Li; Young Seok Ju; Manasa Ramakrishna; Hans Kristian Haugland; Peer Kaare Lilleng; Serena Nik-Zainal; Stuart McLaren; Adam Butler; Sancha Martin; Dominic Glodzik; Andrew Menzies; Keiran Raine; Jonathan Hinton; David Jones; Laura J Mudie; Bing Jiang; Delphine Vincent; April Greene-Colozzi; Pierre-Yves Adnet; Aquila Fatima; Marion Maetens; Michail Ignatiadis; Michael R Stratton; Christos Sotiriou; Andrea L Richardson; Per Eystein Lønning; David C Wedge; Peter J Campbell
Journal:  Nat Med       Date:  2015-06-22       Impact factor: 53.440

9.  SomaticSignatures: inferring mutational signatures from single-nucleotide variants.

Authors:  Julian S Gehring; Bernd Fischer; Michael Lawrence; Wolfgang Huber
Journal:  Bioinformatics       Date:  2015-07-10       Impact factor: 6.937

10.  Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Authors:  David Brown; Dominiek Smeets; Borbála Székely; Denis Larsimont; A Marcell Szász; Pierre-Yves Adnet; Françoise Rothé; Ghizlane Rouas; Zsófia I Nagy; Zsófia Faragó; Anna-Mária Tőkés; Magdolna Dank; Gyöngyvér Szentmártoni; Nóra Udvarhelyi; Gabriele Zoppoli; Lajos Pusztai; Martine Piccart; Janina Kulka; Diether Lambrechts; Christos Sotiriou; Christine Desmedt
Journal:  Nat Commun       Date:  2017-04-20       Impact factor: 14.919

View more
  51 in total

1.  Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.

Authors:  Lan Cao; Ahmed Basudan; Matthew J Sikora; Amir Bahreini; Nilgun Tasdemir; Kevin M Levine; Rachel C Jankowitz; Priscilla F McAuliffe; David Dabbs; Sue Haupt; Ygal Haupt; Peter C Lucas; Adrian V Lee; Steffi Oesterreich; Jennifer M Atkinson
Journal:  Cancer Lett       Date:  2019-06-20       Impact factor: 8.679

2.  Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.

Authors:  Ahmed Basudan; Nolan Priedigkeit; Ryan J Hartmaier; Ethan S Sokol; Amir Bahreini; Rebecca J Watters; Michelle M Boisen; Rohit Bhargava; Kurt R Weiss; Maria M Karsten; Carsten Denkert; Jens-Uwe Blohmer; Jose P Leone; Ronald L Hamilton; Adam M Brufsky; Esther Elishaev; Peter C Lucas; Adrian V Lee; Steffi Oesterreich
Journal:  Mol Cancer Res       Date:  2018-10-24       Impact factor: 5.852

3.  APOBEC3H Subcellular Localization Determinants Define Zipcode for Targeting HIV-1 for Restriction.

Authors:  Daniel J Salamango; Jordan T Becker; Jennifer L McCann; Adam Z Cheng; Özlem Demir; Rommie E Amaro; William L Brown; Nadine M Shaban; Reuben S Harris
Journal:  Mol Cell Biol       Date:  2018-11-13       Impact factor: 4.272

4.  Bone metastasis: evaluation of 1100 patients with breast cancer.

Authors:  Koray Başdelioğlu
Journal:  Int J Clin Exp Pathol       Date:  2021-03-01

Review 5.  Lymph Nodes in Breast Cancer - What Can We Learn from Translational Research?

Authors:  Florentia Peintinger; Roland Reitsamer; Marjolein L Smidt; Thorsten Kühn; Cornelia Liedtke
Journal:  Breast Care (Basel)       Date:  2018-09-25       Impact factor: 2.860

Review 6.  Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery?

Authors:  Toralf Reimer; Jutta Engel; Marcus Schmidt; Birgitte Vrou Offersen; Marjolein L Smidt; Oreste David Gentilini
Journal:  Breast Care (Basel)       Date:  2018-08-24       Impact factor: 2.860

Review 7.  Bone Metastasis: Find Your Niche and Fit in.

Authors:  Weijie Zhang; Igor Bado; Hai Wang; Hin-Ching Lo; Xiang H-F Zhang
Journal:  Trends Cancer       Date:  2019-01-17

8.  The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.

Authors:  Jennifer L McCann; Madeline M Klein; Evelyn M Leland; Emily K Law; William L Brown; Daniel J Salamango; Reuben S Harris
Journal:  J Biol Chem       Date:  2019-06-19       Impact factor: 5.157

Review 9.  Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.

Authors:  Alexios-Fotios A Mentis; Petros D Grivas; Efthimios Dardiotis; Nicholas A Romas; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2020-04-24       Impact factor: 9.261

10.  APOBEC3B Nuclear Localization Requires Two Distinct N-Terminal Domain Surfaces.

Authors:  Daniel J Salamango; Jennifer L McCann; Özlem Demir; William L Brown; Rommie E Amaro; Reuben S Harris
Journal:  J Mol Biol       Date:  2018-05-19       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.